Premium
Proteomic analysis of the neuroprotective mechanisms of acupuncture treatment in a Parkinson's disease mouse model
Author(s) -
Jeon Songhee,
Kim Youn Jung,
Kim SeungTae,
Moon Woongjoon,
Chae Younbyoung,
Kang Minjeong,
Chung MiYoung,
Lee Hyangsook,
Hong MiSook,
Chung JooHo,
Joh Tong H.,
Lee Hyejung,
Park HiJoon
Publication year - 2008
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.200700955
Subject(s) - mptp , neuroprotection , neurodegeneration , substantia nigra , tyrosine hydroxylase , parkinson's disease , pharmacology , medicine , dopaminergic , dopamine , disease
Acupuncture is frequently used as an alternative therapy for Parkinson's disease (PD), and it attenuates dopaminergic (DA) neurodegeneration in the substantia nigra (SN) in PD animal models. Using proteomic analysis, we investigated whether acupuncture alters protein expression in the SN to favor attenuation of neuronal degeneration. In C57BL/6 mice treated with 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine (MPTP, 30 mg/kg/day), intraperitoneal (i.p.) for 5 days, 2 or 100 Hz electroacupuncture (EA) was applied at the effective and specific acupoint, GB34, once a day for 12 consecutive days from the first MPTP treatment. Both treatments in MPTP mice led to restoration of behavioral impairment and rescued tyrosine hydroxylase (TH)‐positive DA neurodegeneration. Using peptide fingerprinting MS, we identified changes in 22 proteins in the SN following MPTP treatment, and nine of these proteins were normalized by EA. They were involved in cell death regulation, inflammation, or restoration from damage. The levels of cyclophilin A (CypA), which is a neuroprotective agent, were unchanged by MPTP treatment but were increased in MPTP‐EA mice. These results suggest that acupoint GB34‐specific EA changes protein expression profiles in the SN in favor of DA neuronal survival in MPTP‐treated mice, and that EA treatment may be an effective therapy for PD patients.